In these cases, tumour necrotic factor (TNF) alpha blockade emerges as a valid therapeutic option, as high levels of TNF alpha and its soluble receptor have been detected in the serum and aqueous humour of patients with active BD [10, 39]. Here, TNF is linked to Behcet disease.